Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Profit After Tax: 2019-2024

Historic Profit After Tax for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$49.4 million.

  • Compass Therapeutics' Profit After Tax fell 36.05% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.8 million, marking a year-over-year decrease of 37.79%. This contributed to the annual value of -$49.4 million for FY2024, which is 16.19% down from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Profit After Tax is -$49.4 million, which was down 16.19% from -$42.5 million recorded in FY2023.
  • Compass Therapeutics' 5-year Profit After Tax high stood at -$37,483 for FY2020, and its period low was -$82.2 million during FY2021.
  • For the 3-year period, Compass Therapeutics' Profit After Tax averaged around -$43.7 million, with its median value being -$42.5 million (2023).
  • In the last 5 years, Compass Therapeutics' Profit After Tax plummeted by 178.58% in 2021 and then skyrocketed by 52.27% in 2022.
  • Over the past 5 years, Compass Therapeutics' Profit After Tax (Yearly) stood at -$37,483 in 2020, then climbed by 15.09% to -$29.5 million in 2020, then plummeted by 178.58% to -$82.2 million in 2021, then skyrocketed by 52.27% to -$39.2 million in 2022, then declined by 8.33% to -$42.5 million in 2023, then dropped by 16.19% to -$49.4 million in 2024.